2021 American Transplant Congress Archives - Page 6 of 139

ATC 2021 Virtual Connect is an all-new, completely enhanced virtual meeting experience. The ATC program is built in Eastern Time Zone.

5:05pm-5:10pm: Validation of a Novel Gene Expression Biomarker of Rejection Following Liver Transplantation

J. Levitsky¹, M. Kandpal¹, T. Whisenant², K. Guo¹, S. Kurian³, M. Abecassis⁴

Biomarkers, Immune Assessment and Clinical Outcomes - II • Virtual

6:00pm-6:05pm: Desensitization Using Clazakizumab® (anti-il-6) in Highly-hla Sensitized Patients Awaiting Kidney Transplant (nct03380962)

A. A. Vo¹, N. Ammerman¹, E. Huang¹, M. Toyoda², S. Ge², A. Peng¹, R. Najjar¹, S. Sethi¹, S. Williamson¹, C. Myers¹, K. Lim¹, M. Gillespie¹, S. Jordan¹

Kidney Desensitization/KPD • Virtual

6:00pm-6:05pm: Economic and Clinical Benefit of Cmv Matching in Kidney Transplantation

D. Axelrod¹, S. Chang², A. Olyaei³, D. Malinoski³, D. Norman³, K. Lentine⁴, M. Schnitzler⁴, D. Segev⁵, J. Lockridge³

The Metabolism Milleu: Updates in Pharmacokinetics and Pharmacogenomics • Virtual

6:00pm-6:05pm: Improved Outcomes Over Time of Extended Criteria Donor Grafts for Acute-on-chronic Liver Failure

T. Kitajima, T. Ivanics, D. Moonka, T. Shamaa, A. Mohamed, K. Delvecchio, K. Collins, M. Rizzari, A. Yoshida, M. Abouljoud, S. Nagai

MELD, Allocation and Donor Issues • Virtual

6:00pm-6:05pm: Mapping Chronic Kidney Disease (CKD) and Acute Kidney Injury (AKI) in Kidney Transplant Biopsies Reveals Two Classes of Early AKI That Differ in Their Response-to-Wounding

P. Halloran¹, J. Reeve¹, G. Böhmig², O. Viklicky³, M. Myslak⁴, G. Gupta⁵, &. the INTERCOMEX Study Group⁶

Kidney Complications • Virtual

6:00pm-6:05pm: Posttransplant Malignancy in HIV+ Kidney Transplant Recipients

D. Sawinski¹, R. Fitzsimmons¹, J. Locke², J. Trofe-Clark¹, B. Shelton², P. Reese¹, E. Blumberg¹

Infections in Kidney Recipients • Virtual

6:00pm-6:05pm: Pregnancy Outcomes in 39 Lung Transplant Recipients

S. Constantinescu¹, L. A. Coscia², A. Yusuf², S. Rao³, M. J. Moritz⁴

When Opportunity Knocks... Identifying Interventions to Optimize Lung Transplant Outcomes • Virtual

6:05pm-6:10pm: Belatacept Pharmacokinetic Analysis Comparing Belatacept Early Steroid Withdrawal Trial (BEST) with Benefit and Benefit-ext Trials

A. Bickenbach¹, M. McGowan¹, B. Miyagawa², T. Mizuno², A. Shields³, A. Christianson¹, P. West-Thielke⁴, J. Leone⁵, E. Woodle¹, D. Kaufman⁶, A. Wiseman⁷, A. Matas⁸, A. Vinks²

The Metabolism Milleu: Updates in Pharmacokinetics and Pharmacogenomics • Virtual

6:05pm-6:10pm: Guiding Therapeutic Plasma Exchange for Amr Treatment in Lung Transplant Recipients Using Serial Dilution in Single Antigen Bead Assay

O. A. Timofeeva¹, J. Choe², M. Alsammak², E. J. Yoon², S. Geier², K. Carney², J. Au², A. Diamond², J. A. Galli², K. Shenoy², A. Mamary², S. Seghal², P. Mullhal², Y. Toyoda², N. Shigemura², F. Cordova², G. Criner², J. Brown²

When Opportunity Knocks... Identifying Interventions to Optimize Lung Transplant Outcomes • Virtual

6:05pm-6:10pm: Impact of Transplant Center Volume on Utilization of and Outcomes Following Donation After Circulatory Death Liver Transplantation in the United States

S. Kumar¹, S. Lin², J. D. Schold²

MELD, Allocation and Donor Issues • Virtual